Keyword: Alnylam Pharmaceuticals
The path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from NICE. Fortunately for the drugmaker, that decision was reversed.
Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.
“Game-changing” is just one way analysts and regulators described Alnylam's approval for RNAi drug Onpattro. But the biotech still has work to do.
Alnylam’s first drug approval could come any day now, and to get ready, the company is bulking up—in more ways than one.
Alnylam highlights the power of family in hereditary diseases, putting the spotlight on one extended family in its new disease awareness campaign.
Top drugmakers and pharma's industry kept mum in the wake of Merck CEO Ken Frazier's decision to exit a Trump manufacturing panel.